AccuRna
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $4.2M
Overview
AccuRna develops novel drug delivery platforms for nucleic acid therapeutics including siRNA, ASO, miRNA, and mRNA to treat refractory diseases.
OncologyInfectious Disease
Technology Platform
Novel drug delivery systems (DDS) for nucleic acid therapeutics capable of delivering both short-chain (ASO, siRNA, miRNA) and long-chain (mRNA) RNA modalities, with potential application to CRISPR-Cas systems.
Opportunities
Growing demand for nucleic acid therapeutics post-COVID-19 creates significant partnership opportunities for delivery platform companies; versatility across RNA modalities could attract multiple pharmaceutical collaborators.
Risk Factors
As a preclinical platform company with undisclosed validation data, technical risks around delivery efficacy and safety remain unproven; intense competition in RNA delivery from better-funded companies presents commercial challenges.
Competitive Landscape
Competes with established RNA delivery companies like Alnylam (GalNAc-conjugates), Moderna/BioNTech (LNPs), and Arrowhead Pharmaceuticals; differentiation through platform versatility across multiple nucleic acid types rather than modality-specific solutions.